{"prompt": "['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 113 of 122', 'Study Period', 'Initial Dose Escalation', 'Up-Dosing', 'Early', 'Study Visit', 'Day 1 [1]', 'Day 2 [2]', 'At Study Site', 'At 80 mg', 'At 300 mg', 'Unsched [3]', 'Disc [4]', 'Interval', 'na', 'na', 'Every 2 weeks', 'Varies', 'Varies', 'Varies', 'Varies', 'Window (Days)', 'na', 'na', '3', '3', '3', 'na', '3', 'Laboratory Evaluations [19]', 'Urine pregnancy test [20]', 'X', 'X', 'X (optional)', 'X', 'Blood sample for basophil activation test (BAT)', 'X', '[1]', 'Day 1 HRQOL questionnaires and bespoke questions are to be administered after eligibility is confirmed and must be completed before randomization.', 'Day 1 activities must begin within 28 days after obtaining signed consent/assent and should be the same day as randomization', '(within', '3', 'days', 'after', 'randomization only if the same day is not feasible). The timing of day 1 study product administration, vital signs, and assessment of allergic reactions', 'for initial dose escalation is presented in Table 3.', '[2]', 'Day 2 should be the next consecutive day after day 1. If circumstances (eg, an intercurrent illness) create a safety risk, day 2 may be delayed up to', '7 days after day 1.', '[3]', \"Anytime necessary to assess or follow up adverse events, at the subject's request, or per investigator decision. Perform procedures, spirometry, and\", 'laboratory tests as appropriate.', '[4]', 'For subject unable to complete initial dose escalation or up-dosing; approximately 14 days after the last dose.', '[5]', 'Instruct subject and parent/caregiver to complete HRQOL questionnaires and bespoke questions at the start of the visit before other procedures (unless', 'specified otherwise). The same parent/caregiver should complete all relevant questionnaires during the study.', 'For age-relevant questionnaires, subject who transitions from one age group to the next age group during the study will complete the version first used.', '[6]', 'Parent/caregiver: EQ-5D-5L, EQ-5D-Y proxy (for subject aged 4-7 years); subject aged 8-12 years: EQ-5D-Y; subject aged 13-17 years: EQ-5D-5L.', 'In addition, instruct subject and parent/caregiver to complete the questionnaire as follows:', 'Before leaving the study site if severe dose-related allergy symptoms occur during an up-dosing visit (Section 8.5.1), and 1 week', 'later.', 'When allergy symptoms due to study product or food allergen exposure are reported to the study site and assessed as severe (Section 8.5.6.3), and', '1 week later.', '[7]', 'Subject discontinuing before the start of maintenance: Subject and parent/caregiver will complete relevant EQ-5D, FAQLQ, and FAIM questionnaires', 'at early discontinuation and 12 and 18 months after day 1.', '[8]', 'For parent/caregiver.', '[9] Parent/caregiver of subject aged 12 years: FAQLQ-PF and FAIM-PF; parent/caregiver of subject aged 13-17 years: FAQLQ-PFT and', 'FAIM-PFT;', 'subject aged 8-12 years: FAQLQ-CF and FAIM-CF; subject aged 13-17 years: FAQLQ-TF and FAIM-TF.', '[10]', 'For subject aged > 6 years, obtain PEFR at approximately the same time of day for each assessment visit (eg, morning, afternoon); record the best', 'result of 3 attempts. Obtain spirometry (FEV1) if PEFR shows a clinically relevant reduction, subject has clinical deterioration (eg, active wheeze on', 'physical examination), or as clinically indicated at unscheduled visits; record the best result of 3 attempts (if unable to successfully obtain, record', 'attempts and investigator assessment).', 'For subject aged 4-5 years, obtain PEFR; record results (if unable to successfully obtain, record attempts and investigator assessment).']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 114 of 122', '[11] For subject with asthma. Evaluate asthma severity per NHLBI 2007 criteria (Table 19).', '[12]', 'Symptom-directed: Assess systems per standard of care at the study site or as clinically indicated by symptoms.', 'Complete:', 'Assess systems (eg, general appearance, head, eyes, ears, nose, mouth, skin, heart, lungs, lymph nodes, gastrointestinal, genitourinary,', 'neurologic, and skeletal).', '[13] Instruct subject to avoid peanut during the study. Provide food/peanut allergy education (including recognition of an allergic reaction, symptoms of', 'anaphylaxis, administration of epinephrine auto-injector, anaphylaxis action plan, ways to minimize accidental exposure to peanut) per standard of care', 'at the study site.', '[14]', 'For', 'subject', 'with GI adverse events of interest (Section 8.5.6.2), instruct subject aged > 8 years and parent/caregiver to complete the PEESS v2.0', 'questionnaire while subject is symptomatic, at early discontinuation or study exit, and during safety follow-up.', 'Subject with unresolved adverse events at early discontinuation will have safety follow-up per Appendix 7.', '[15]', 'Review medications since previous visit. Instruct subject to discontinue antihistamines at least 5 half-lives of the medication before initial', \"dose-escalation day 1. Review the prescribing information to determine the half-life of each medication for the subject's relevant age group.\", '[16]', 'Administer study product at the study site per the dose-escalation schedule (up-dosing, Table 4) and dose modification guidelines (Section 8.5.3).', 'Measure blood pressure and heart rate and assess signs/symptoms of allergic reaction at 15-30 minutes postdose and every 30 minutes thereafter until', '90 minutes postdose or end of observations for allergy symptoms, whichever is last.', '[17]', 'Review instructions for administration of study product at home. Instruct that subject withhold study product when it will be administered at the study', 'site.', '[18]', 'On the day after day 2 and the day after up-dosing visits: Contact subject and parent/caregiver by telephone for adverse events review and to inquire', 'about compliance with study product dosing.', '[19]', 'Refer to the laboratory manual for sample collection and processing.', '[20]', 'For all females of childbearing potential.', 'ACT, Asthma Control Test; C-ACT, Childhood Asthma Control Test; disc, discontinuation; EQ-5D, European Quality of Life 5-Dimensions health', 'questionnaire; EQ-5D-5L, EQ-5D 5-Levels; EQ-5D-Y, EQ-5D Youth; FAIM, Food Allergy Independent Measure; FAIM-CF, FAIM - child form; FAIM-PF,', 'FAIM - parent form; FAIM-PFT, FAIM - parent form teenager; FAIM-TF, FAIM - teenager form; FAQL-PB, Food Allergy Quality of Life - Parental Burden;', 'FAQLQ, Food Allergy Quality of Life Questionnaire; FAQLQ-CF, FAQLQ - child form; FAQLQ-PF, FAQLQ - parent form; FAQLQ-PFT, FAQLQ - parent', 'form teenager; FAQLQ-TF, FAQLQ - teenager form; FEV1, forced expiratory volume in the first second of expiration; GI, gastrointestinal; HADS, Hospital', 'Anxiety and Depression Scale; HRQOL, health-related quality of life; na, not applicable; NHLBI, National Heart, Lung, and Blood Institute; PEESS v2.0,', 'Pediatric Eosinophilic Esophagitis Symptom Scores version 2.0; PEFR, peak expiratory flow rate; SCORAD, scoring atopic dermatitis; TNSS, Total Nasal', 'Symptom Score.']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 115 of 122', 'Appendix 5: Study Schedule of Activities for AR101 Treatment: Maintenance', 'Study Period', 'Maintenance', 'Unsched [1]', 'ED [2]', 'Exit [2]', 'OLFC', 'RWPC', 'Study Visit (Week)', '1, 5, 9', '13', '17,21', '25', '[3]', '[4]', '29', '33, 37', '41', '45,49', 'na', 'na', '53', 'Interval', 'Every 4 weeks', 'Varies', 'Varies', 'na', 'Window (Days)', '7', 'na', '3', '7', 'HRQOL Questionnaires and Bespoke Questions [5]', 'EQ-5D [6]', 'X', 'X [6]', 'X [6]', 'X', 'X [7]', 'X', 'FAQL-PB [8]', 'X', 'X', 'X', 'HADS [8]', 'X', 'X', 'X', 'X', 'FAQLQ, FAIM [9]', 'X', 'X [9]', 'X [9', 'X [7]', 'X', 'Bespoke global assessment of HRQOL', 'X', 'X', 'X', 'X', 'Bespoke assessment of control and confidence', 'X', 'X', 'X', 'Bespoke assessment of food challenge outcomes', 'X [10]', 'X [10]', 'TSQM-9', 'X', 'X', 'Bespoke exit questionnaire', 'X', 'X', 'Exit interview [11]', 'X', 'X', 'General Activities', 'Weight, height', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Vital signs (blood pressure, heart rate, temperature)', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'ACT/C-ACT, SCORAD, TNSS (if completed at screening)', 'X', 'X', 'X (optional)', 'X', 'X', 'PEFR [12]', 'X', 'X', 'X (optional)', 'X', 'X', 'Asthma evaluation [13]', 'X', 'X', 'X (optional)', 'X', 'X', 'Symptom-directed physical examination [14]', 'X', 'X', 'X', 'Complete physical examination [14]', 'X (optional)', 'X', 'X', 'Diet/food allergen exposure review', 'X', 'X', 'X', 'Food allergy instruction [15]', 'X', 'X (optional)', 'X', 'X', 'Contraception review', 'X', 'X (optional)', 'Adverse events review [16]', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Concomitant medications review & instruction [17]', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Study product administration [18]', 'X (optional)']", "completion": ""}